{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "PRE", "regularMarketPrice": 0.78, "exchangeTimezoneShortName": "EDT", "exchangeTimezoneName": "America/New_York", "currency": "USD", "market": "us_market", "esgPopulated": false, "messageBoardId": "finmb_325748154", "gmtOffSetMilliseconds": -14400000, "shortName": "ABVC Biopharma, Inc.", "longName": "ABVC BioPharma, Inc.", "regularMarketChangePercent": -5.6375566, "exchange": "NCM", "regularMarketChange": -0.046600044, "regularMarketTime": 1684180557, "regularMarketDayHigh": 0.7933, "regularMarketDayRange": "0.76 - 0.7933", "regularMarketDayLow": 0.76, "regularMarketVolume": 30848, "regularMarketPreviousClose": 0.8266, "bid": 0.0, "ask": 0.0, "bidSize": 29, "askSize": 12, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.7803, "averageDailyVolume3Month": 58103, "averageDailyVolume10Day": 43630, "fiftyTwoWeekLowChange": 0.27999997, "ipoExpectedDate": "2021-08-03", "prevName": "American BriVision (Holding) Corporation", "nameChangeDate": "2023-05-15", "averageAnalystRating": "3.0 - Hold", "tradeable": false, "cryptoTradeable": false, "fiftyTwoWeekLowChangePercent": 0.55999994, "fiftyTwoWeekRange": "0.5 - 2.33", "fiftyTwoWeekHighChange": -1.55, "fiftyTwoWeekHighChangePercent": -0.66523606, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 2.33, "dividendDate": 1557273600, "earningsTimestamp": 1680302985, "earningsTimestampStart": 1684234740, "earningsTimestampEnd": 1684497600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.55, "epsForward": -0.44, "epsCurrentYear": -0.28, "priceEpsCurrentYear": -2.7857141, "sharesOutstanding": 33080700, "bookValue": 0.095, "fiftyDayAverage": 0.6726, "fiftyDayAverageChange": 0.1074, "fiftyDayAverageChangePercent": 0.15967886, "twoHundredDayAverage": 0.74741, "twoHundredDayAverageChange": 0.032589972, "twoHundredDayAverageChangePercent": 0.043603875, "marketCap": 25802946, "forwardPE": -1.7727273, "priceToBook": 8.210526, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "firstTradeDateMilliseconds": 1100097000000, "priceHint": 4, "displayName": "ABVC BioPharma", "symbol": "ABVC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "44370 Old Warm Springs Boulevard", "city": "Fremont", "state": "CA", "zip": "94538", "country": "United States", "phone": "(510)-668-0881", "website": "https://www.abvcpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.", "fullTimeEmployees": 19, "companyOfficers": [{"maxAge": 1, "name": "Mr. Eugene  Jiang", "age": 36, "title": "Chairman & Chief Bus. Officer", "yearBorn": 1986, "fiscalYear": 2022, "totalPay": {"raw": 200000, "fmt": "200k", "longFmt": "200,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Howard  Doong M.D., Ph.D.", "age": 65, "title": "Pres & CEO", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 200000, "fmt": "200k", "longFmt": "200,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Leeds  Chow", "age": 33, "title": "CFO & Principal Accounting Officer", "yearBorn": 1989, "fiscalYear": 2022, "totalPay": {"raw": 130000, "fmt": "130k", "longFmt": "130,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Chi-Hsin  King Ph.D.", "age": 74, "title": "Chief Scientific Officer", "yearBorn": 1948, "fiscalYear": 2022, "totalPay": {"raw": 200000, "fmt": "200k", "longFmt": "200,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tsung-Shann  Jiang Ph.D.", "age": 68, "title": "Chief Strategy Officer, Member of Scientific Advisory Board & Director", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 200000, "fmt": "200k", "longFmt": "200,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}